In the final episode, experts at UCSD and La Jolla Institute discuss current clinical trials of a cancer vaccine and future directions for neoantigen vaccines. Custom-made Cancer Therapy: Neoantigen ...

Recent advances in molecular diagnostics underscore the need for improved sensitivity and specificity in cancer detection, yet multi-type nucleic acid response logic gates remain underexplored. Here, ...

Objective To develop a best practice guide for managing people with plantar heel pain (PHP). Methods Mixed-methods design including systematic review, expert interviews and patient survey. Data ...

Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...

Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is ...

Taysha Gene Therapies (TSHA) reported a net loss of $109.0 million for the full year ending December 31, 2025, translating to a loss of $0.34 per share. This marks an increase from the $89.3 million ...